Open AccessPrognostic effects of O6 -Methylguanine DNA methyltransferase promoter hypermethylation in high-grade glioma patients with carmustine wafer implants
Author(s) -
Mao-Yu Chen,
PingChing Pai,
Shih Ming Jung,
ChiCheng Chuang,
Chen-Nen Chang,
KuoChen Wei
Publication year - 2017
Publication title -
formosan journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 8
eISSN - 2213-5413
pISSN - 1682-606X
DOI - 10.4103/fjs.fjs_18_17
Subject(s) - carmustine , medicine , glioma , methyltransferase , chemotherapy , surgery , oncology , methylation , cyclophosphamide , cancer research , chemistry , gene , biochemistry
Background: Local chemotherapy with carmustine (BCNU) wafer implantation has survival benefits for malignant glioma patients. However, available data regarding its association with O6-methylguanine-DNA-methyltransferase (MGMT) are scant.Purpose: To evaluate whether MGMT hypermethylation has prognostic effects in malignant glioma patients with interstitial BCNU wafer implants.Methods: From September 2004 to August 2007, 32 patients with malignant gliomas underwent surgical resection plus interstitial BCNU wafer implantation at our hospital.Results and Conclusion: BCNU wafer implantation was performed in 18 patients with newly diagnosed gliomas and in 14 with recurrent gliomas. All patients had a Karnofsky performance status of ≥70. The median age was 51 years. At a median follow-up of 31 months, the 1- and 2-year overall survival (OS) rate was 43% and 22%, respectively. OS rates did not significantly differ between the newly diagnosed and recurrent patients. Gross total tumor resection was achieved in 19 (59%) patients, and MGMT hypermethylation was noted in 13 (41%) tumor specimens. Multivariate analysis demonstrated that patients with MGMT hypermethylation in their tumors and gross total tumor removal have more favorable survival rates (P = 0.03)